Chester County News and Community Website
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), headquartered in West Chester, PA, is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. For more information, visit www.verrica.com.
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said it has dosed the first patient in its global Phase 3 clinical program evaluating YCANTH (VP-102) for the treatment of …
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion Read More WEST CHESTER, PA — Verrica Pharmaceuticals (Nasdaq: VRCA) raised approximately $50 million through a private investment in public equity, a move the company said will retire its debt facility, strengthen …
Verrica’s $50 Million PIPE Deal Sparks Big Questions About Its Next Growth Phase Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported third-quarter results that highlight accelerating commercial traction for its lead product, YCANTH®, alongside major regulatory and clinical milestones that broaden …
Verrica Posts Strong Q3 as YCANTH Momentum Builds and Late-Stage Pipeline Advances Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled compelling new data from its Phase 2 study of VP-315, a first-in-class oncolytic peptide immunotherapy, showing strong local immune activation …
New Cancer Data Hints at a Surgery-Free Future — Verrica’s VP-315 Shows Big Promise Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has provided positive feedback supporting …
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will present new data on its investigational oncolytic peptide therapy, VP-315, for the treatment of basal cell carcinoma …
Verrica Pharmaceuticals to Present Phase 2 Data on VP-315 at Major Immunotherapy Conference Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that its partner Torii Pharmaceutical Co. Ltd., now a subsidiary of Shionogi & Co., Ltd., has received approval from Japan’s …
Verrica Secures $10 Million Milestone as YCANTH Wins Approval in Japan Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that President and Chief Executive Officer Jayson Rieger, PhD, MBA, will present at the H.C. Wainwright 27th Annual Global Investment …
Verrica Pharmaceuticals CEO to Present at H.C. Wainwright Global Investment Conference Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported second-quarter 2025 revenue of $12.7 million, driven by continued commercial momentum for its lead product, YCANTH®, and milestone payments from …
Verrica Pharmaceuticals Posts Strong Q2 Growth, Advances Basal Cell Carcinoma Program Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced a significant surge in demand for its lead product, YCANTH®, in the second quarter of 2025, reporting 13,434 dispensed applicator …
Verrica Reports Strong Q2 Growth as YCANTH Demand Accelerates Read More